Biochemical and Biophysical Research Communications 409 (2011) 137–141

Contents lists available at ScienceDirect

Biochemical and Biophysical Research Communications

journal homepage: www.elsevier.com/locate/ybbrc

A new myelin protein, TPPP/p25, reduced in demyelinated lesions is enriched in cerebrospinal fluid of multiple sclerosis

Orsolya Vincze [a,1], Judit Oláh [a,1], Dénes Zádori [b], Péter Klivényi [b], László Vécsei [b], Judit Ovádi [a,*]

[a] Institute of Enzymology, Biological Research Center, Hungarian Academy of Sciences, Budapest, Hungary
[b] Department of Neurology, University of Szeged, Szeged, Hungary

ARTICLE INFO

Article history:
Received 26 April 2011
Available online 1 May 2011

Keywords:
Tubulin Polymerization Promoting Protein/p25
Multiple sclerosis
Cerebrospinal fluid

ABSTRACT

Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease with variable extent of remyelination coupled with the differentiation of oligodendrocytes, in which Tubulin Polymerization Promoting Protein/p25 (TPPP/p25) plays a crucial role. Previously we reported that the loss of TPPP/p25-positive oligodendrocytes in demyelinated lesions in the brain of MS patients could be a biomarker for MS [2]. In this work we tested the occurrence of TPPP/p25 in the cerebrospinal fluid (CSF) of MS patients, and by elaborating a sensitive assay for quantification of TPPP/p25 we showed that its level is significantly higher than in the case of non-MS patients. Patients with MS were diagnosed at the Department of Neurology, University of Szeged according to the clinical and laboratory diagnostic criteria of McDonald. In non-MS patients no significant pathological changes were detected on magnetic resonance imaging scans, while in MS patients multiple hyperintense T2 lesions in the white matter were detected. Kurtzke Expanded Disability Status Scale scores as well as IgG level and oligoclonal bands of MS patients were demonstrated. The sensitive assay elaborated in this study is based upon Western blot followed by chemiluminescent detection validated by human recombinant protein. The median TPPP/p25 contents in the CSF were 62.8 and 64.7 μg/L for patients with clinically isolated syndromes and relapsing remitting MS, respectively, while this value for non-MS patients was 27.9 μg/L. The enrichment of TPPP/p25 was independent of age, gender and the time period between lumbar puncture and relapse/shub. These data suggest that the TPPP/p25-based assay could be a powerful diagnostic test for MS patients.

1. Introduction

Multiple sclerosis (MS) is a chronic inflammatory disease of unknown origin causing lesions of the ensheathment of axons with myelin [1]. The self-repair mechanisms include remyelination of variable extent which is originated from the migration of the oligodendrocyte (OLG) precursor cells followed by their differentiation into mature OLGs. The depletion of the precursors and/or impaired differentiation could be mechanisms responsible for the lesions ([2] and references therein).

Magnetic resonance imaging (MRI) is an important tool for the diagnosis of MS [3]. The diagnostic McDonald criteria demonstrate the spatial and temporal dissemination of the disease by MRI even at early state of the disease [4]. Also cerebrospinal fluid (CSF) analysis is a useful diagnostic tool to define MS. The presence of oligoclonal bands (OCB) in the CSF is one of the most specific and sensitive tests in MS [5]. However, in certain cases it produces false negative result since some patients remain OCB-negative despite meeting typical criteria for diagnosis of MS. This could be due to the fact that demyelination in MS may occur independent of antibody, or CSF electrophoresis methods may be insensitive to detect local synthesis of antibody in all clinically definite cases of MS. Since a main constituting protein of myelin is the myelin basic protein (MBP), the quantification of its concentration in CSF was proposed to be a diagnostic indicator of myelin breakdown [6,7]. However, the CSF MBP values were found to be very much reduced before and after the acute attack periods and frequently became undetectable [8]. Intensive efforts are directed to search for additional CSF biomarkers in MS [9].

Tubulin Polymerization Promoting Protein/p25 (TPPP/p25), an interacting partner of MBP, is located predominantly in mature

Abbreviations: CSF, cerebrospinal fluid; EDSS, Kurtzke Expanded Disability Status Scale; MRI, magnetic resonance imaging; MS, multiple sclerosis; CIS MS, MS with clinically isolated syndromes; MBP, myelin basic protein; OCB, oligoclonal band; OD, other disease; OIND, other inflammatory neurological disease; OLG, oligodendrocyte; OND, other neurological disease; RR MS, relapsing–remitting MS; TPPP/p25, Tubulin Polymerization Promoting Protein/p25.

* Corresponding author. Address: Institute of Enzymology, H-1113 Karolina út 29, Budapest, Hungary. Fax: +36 1 466 5465.
E-mail address: ovadi@enzim.hu (J. Ovádi).

[1] These authors contributed equally to the work.

0006-291X/$ - see front matter © 2011 Elsevier Inc. All rights reserved.
doi:10.1016/j.bbrc.2011.04.130

OLGs and aggregates in oligodendroglial cytoplasmic inclusions in multiple system atrophy [10,11]. We suggested that its physiological function in OLGs could be the reorganization and stabilization of the microtubular ultrastructures in the course of ensheathment of axons [12]. We quantified the amount of TPPP/p25 in OLGs of human brain tissue from MS patient, and the demyelinated lesions revealed loss of TPPP/p25-positive OLGs within the MS plaques and increased number of TPPP/p25 immunoreactive OLGs in the normal appearing white matter [2]. These recent data suggested impaired differentiation, migration, and activation capacity of OLGs in later disease stages of MS [2]. These observations motivated us to test the appearance of TPPP/p25 in the CSF and serum samples of MS patients which might contribute to a better understanding of the demyelination of the ensheathment of axons.

2. Materials and methods

2.1. Standard protocol approvals, registrations, and patient consents

The study was approved by the Human Investigation Review Board of the University of Szeged, and written informed consent was obtained from each patient who participated in the study.

2.2. TPPP/p25 purification

Human recombinant TPPP/p25 possessing His-tag tail was expressed in *Escherichia coli* BL21 (DE3) cells and isolated on HIS-Select™ Cartridge (Sigma H8286) as described previously [10].

2.3. Protein determination

The protein concentration was measured by the Bradford method [13] using the Bio-Rad protein assay kit.

2.4. Western blot

CSF samples were stored at −70 °C. After thawing, 20 μl CSF sample was mixed with 5 μl sample loading buffer, and was loaded into Tris–Tricine sodium dodecyl sulfate–polyacrylamide gel [14]. The electrophoresis was followed by transfer onto a polyvinylidene fluoride membrane using wet transfer equipment (Sigma). After blocking, TPPP/p25 was detected by using a rat polyclonal anti-TPPP/p25 antibody [15] in 1:5000 dilution. Antibody binding was revealed by using anti-rat IgG coupled with peroxidase (dilution 1:10,000) (Sigma), ECL (enhanced chemiluminescence) Western Blotting Detection reagents (Amersham Biosciences) and Kodak X-Omat AR films. For quantification of the amount of TPPP/p25 in each CSF sample, a standard curve was obtained from the band intensities of the serially diluted samples of human recombinant TPPP/p25 (in the range of 25–250 μg/L, corresponding to 0.25–2.5 ng). The optical density of the immunoreactive bands was determined by ImageJ program, and was used as quantitative data. There was no chemiluminescent reaction, if the anti-TPPP/p25 antibody was omitted, or 5 μg human recombinant TPPP/p25 was added together with the anti-TPPP/p25 antibody.

2.5. Statistical analysis

All statistical analyses were performed with the help of the SPSS Statistics 17.0 software. Before statistical comparisons, we checked the distribution of data populations with the Shapiro–Wilk *W* test, and also performed the Levene's test for the analysis of the homogeneity of variances. The data population of age was distributed normally and equal variances were assumed, so we used independent *t* test and one-way ANOVA for that comparisons, respectively. All of the other examined data populations showed non-Gaussian distribution, so we used nonparametric statistics: the Mann–Whitney *U* test when two groups were compared, and the Kruskal–Wallis test, when there were more than two groups, followed by paired comparisons with the Mann–Whitney *U* test. The null hypothesis was rejected when the *p* level was lower than the value of 0.05 divided by the number of comparisons (in case of three comparisons: $p < 0.016$), and in such cases the differences were considered significant. In the event of Gaussian or of non-Gaussian distributions, data were presented as means (±SD) or medians (and interquartile range), respectively. Furthermore, where statistical analysis revealed significant differences between the groups showing Gaussian distribution, the 95% confidence interval (CI) of mean was also given. For correlation analyses, we used the nonparametric Spearman correlation coefficient.

3. Results

3.1. Patients

Thirty patients (6 men, 24 women; age: 37.9 ± 10.4 years (mean ± SD), duration of disease: 8.0 (3.0–67.5) months (median and interquartile range), disability score corresponding to Kurtzke Expanded Disability Status Scale (EDSS): 1.5 (1.0–2.0) (median and interquartile range)) with relapsing–remitting MS (RR MS) and 14 patients (3 men, 11 women; age: 35.9 ± 12.7 years, duration of disease: 2.5 (1–10.75) months, disability score (EDSS): 0.0 (0.0–0.0)) with clinically isolated syndromes (CIS MS) were included in this study. Patients with MS were diagnosed at the Department of Neurology, University of Szeged. The diagnosis of MS was confirmed according to the clinical and laboratory diagnostic criteria of McDonald [5] meaning that all the MS patients had typical MRI lesions and OCBs in CSF. In non-MS patients the MRI showed no significant pathological changes. At the time of spinal tap, the patients received neither steroid therapy nor vitamin supplementation. The control group comprised 32 individuals (10 men, 22 women; age: 36.9 ± 12.3 years), who underwent spinal tap for diagnostic purposes, but no autoimmune neurological disease was found in their cases. Fourteen patients suffer from other neurological diseases without inflammation (OND such as epilepsy, cavernoma or polyneuropathy), 12 patients suffer from other diseases without manifest neurological involvement (OD such as patients suspected of having subarachnoidal hemorrhage, but the CSF tapping indicate no bleeding) and 6 patients suffer from other inflammatory neurological diseases (OIND e.g. viral or bacterial meningitis).

3.2. TPPP/p25 is present in CSF

Since TPPP/p25 is located predominantly in mature OLGs and plays a crucial role in the myelination/re-myelination processes, we hypothesized its appearance in CSF of MS patients. To test this idea we elaborated a sensitive, specific assay based upon Western blot coupled with chemiluminescent detection (Fig. 1A). The calibration curve showed quantitative relationship for human recombinant TPPP/p25 at concentrations of 25–250 μg/L with a slope of 14.9 ± 0.84 (±SD), an intercept of −270 ± 121 (±SD) and an R^2 of 0.99 (Fig. 1B).

3.3. CSF TPPP/p25 is increased in MS compared to non-MS controls

Patients with MS divided into two groups denoted as CIS and RR patients with clinically isolated syndromes and relapsing remitting MS, respectively, were clinically characterized, and their CSF samples were used to evaluate TPPP/p25 level.